Turn Therapeutics Inc. (TTRX)
Turn Therapeutics develops topical drug candidates for skin conditions and licenses wound care medical devices to partners. It last closed at $8.55 on Nov 17, up 0.00% on the day. The average 12-month price target from 2 analysts is $17.00 (+98.8% from the last close), with a high of $24.00 and a low of $10.00.
Key Stats
Last 12 monthsNot reported for this period.
From TTRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on TTRX in the past 90 days. The average target is $17.00, with a high of $24.00 and a low of $10.00, compared with the last close of $8.55.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 23 | WBB Securities | Upgrade | Hold | $10 |
| Sep 24 | LUCID CAPITAL MARKETS | Initiated | Buy | $24 |
| Sep 14 | WBB Securities | Downgrade | Sell | $10 |
Technical Analysis
The stock is 16% below its 20 day and 36% below its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Jul 17) at $8.51, and the nearest resistance the Pivot at $8.58.
| RSI (14) | 36.50 | Weak, oversold below 30 | Neutral |
| MACD | -0.59 | Below its signal line | Bearish |
| Stochastic | 19.6 | Near the bottom of its range | Oversold |
| ADX (14) | 23.2 | Weak trend | |
| Williams %R | -85.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -174.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −10.1% | Change over 10 sessions | Bearish |
| ATR (14) | $1.02 | Typical daily range, 12.0% of price |
| RSI (14) | 46.54 | Middle of its range | Neutral |
| MACD | 0.87 | Below its signal line | Bearish |
| Stochastic | 11.6 | Near the bottom of its range | Oversold |
| ADX (14) | 44.8 | Strong uptrend | |
| Williams %R | -94.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -85.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −32.6% | Change over 10 sessions | Bearish |
| ATR (14) | $1.97 | Typical daily range, 23.0% of price |
What happened before
See how TTRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in TTRX in the last 90 days.
TTRX Institutional Ownership
Full report →- ▲27 buying vs 7 selling
- ▲Held by funds +3.7 pts
- ▲Funds holding +14
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 43 | 29 | +48.3% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 7.6% | 3.9% | +3.7 pts |
| New / increased | 16 / 11 | 10 / 4 | +92.9% |
| Reduced / sold out | 4 / 3 | 2 / 2 | +75.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TTRX is in one of them and how their past TTRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TTRX in an article yet. Here's the latest on the wider market.
About Turn Therapeutics
Turn Therapeutics is a drug development company based in Westlake Village, California. It is developing GX-03, a topical treatment for inflammatory skin conditions, with programs aimed at moderate to severe eczema and nail fungus, known as onychomycosis. The company also licenses wound care and dermatitis medical devices to commercial partners, including Medline. Its drug candidate uses polyhexanide, a polymer with a long history of use in wound care.
- Headquarters
- Westlake Village, CA

